SBFM
Sunshine Biopharma Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.93
−12.01%Oct 22, 2026, 13:00 UTC
Sunshine Biopharma announced a one-for-twenty reverse stock split of its common stock, effective at market open on October 26, 2026, to regain compliance with NASDAQ, INC.'s minimum bid price requirement.
Source:Oct 8, 2026, 12:00 UTC
Sunshine Biopharma Inc. announced the pricing of a public offering expected to generate approximately $6.0 million in gross proceeds, comprising 10,909,083 common or pre-funded units with two Series D warrants per unit.
Sep 16, 2026, 13:00 UTC
Sunshine Biopharma Inc. advanced its lead Coronavirus drug candidate into IND-enabling studies.
Source:Aug 31, 2026, 13:00 UTC
Health Canada approved Sunshine Biopharma's generic Atenolol tablets (25mg, 50mg, 100mg) for the Canadian market to treat and manage cardiovascular conditions.
Source:Aug 28, 2026, 20:20 UTC
Dr. Andrew Keller departed as director of Sunshine Biopharma Inc. upon expiry of his term.
Aug 4, 2026, 12:31 UTC
Sunshine Biopharma Inc. received regulatory approval to launch its 2mg generic Dienogest tablets in Canada.
Source:Jul 28, 2026, 12:00 UTC
Health Canada approved Sunshine Biopharma's generic Ondansetron tablets for the Canadian market.
Source: